What Syncol Max Treats: Main Uses and Benefits

This combination is commonly used for the symptomatic relief of discomfort related to menstrual periods. It is applied in situations involving distressing symptoms of the cycle, including menstrual cramps, headache, backache, bloating, water-weight gain, and tiredness.

Targeted Relief for Multi-Symptom Episodes

This medication is relevant for easing symptoms related to systemic imbalance that accompany pain. It is commonly used across conditions presenting with recurrent or episodic manifestations. It is generally applied in scenarios where additional symptomatic support is needed, such as when multiple symptoms occur together, to support the moderation of discomfort. This action provides supportive relief that contributes to easing the overall symptom load and may assist with maintaining functional stability during periods of heightened symptoms.

Regulatory References

1. DailyMed label for Midol Complete

Eligibility Map: Who can and cannot use Syncol Max — official regulatory information

This information reflects the official eligibility and non-eligibility classifications documented in regulatory labeling for this combination product.

Eligibility classifications (high-level)

• Eligibility severity classification: Includes "Do not use" (Absolute Prohibition), "Ask a doctor before use" (Conditional Use Restriction), and "Ask a health professional before use" (Physiological State Consultation).

Resulting eligibility structure

Official regulatory documents define the primary eligible group as individuals aged 12 and above who do not have specific allergies or co-existing conditions. The label places strict prohibitions on use with other acetaminophen products and chronic heavy alcohol consumption, while advising consultation for those with pre-existing organ conditions or concurrent use of certain medications, thereby establishing clear limits for non-prescription eligibility.

Interactions with other medicines and products

The interaction profile for this combination medicine is structured around mandatory restrictions and warnings for co-administered substances, based strictly on official regulatory documents.

Interaction-Related Restrictions and Warnings

Co-administration with any other drug containing acetaminophen is a formal prohibition documented in the label. This restriction is established to prevent the risk of severe liver damage from inadvertently exceeding the maximum daily dose.

Additive pharmacodynamic effects are officially documented for substances that impact the Central Nervous System (CNS). Use with sedatives or tranquilizers may increase the severity of drowsiness due to the antihistamine component. Conversely, the product requires the user to limit the intake of all caffeine-containing foods, beverages, or medicines to prevent excessive CNS stimulation, such as nervousness or rapid heart rate.

Alcoholic beverages must be avoided, and the label identifies that individuals who consume three or more alcoholic drinks every day are at a specific, heightened risk of a severe toxic interaction with the acetaminophen component. Additionally, the label requires consultation with a healthcare professional before using the product if the patient is taking the blood thinning drug warfarin, which indicates an established, clinically relevant exposure-modifying risk.

Regulatory Context

The documented interaction classifications include a Contraindicated Combination (with other acetaminophen products) and a requirement for Use with Caution or professional consultation for several key substance groups, including anticoagulants and CNS depressants. No timing-based dose separation rules are specified in the official regulatory documentation.

Syncol Max functions as an inhibitor of the Janus Kinase (JAK) pathway, reducing the phosphorylation and subsequent nuclear translocation of Signal Transducers and Activators of Transcription (STAT) proteins. This mechanism involves the intracellular inhibition of JAK enzymes, blocking the signal transduction initiated by extracellular cytokine binding. By modulating the phosphorylation of STAT proteins, the drug affects T-cell differentiation and proliferation, which influences the cellular composition and signaling environment of the gastrointestinal mucosa. This mechanistic cascade results in the decreased expression of pro-inflammatory cytokines, including Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-alpha). The drug’s activity also modulates the signaling required for maintaining the integrity of the tight junction proteins and adherence junctions in the epithelial layer.

Syncol Max is administered via the oral route as a fixed-dose combination caplet or tablet. The use of this product is based on a defined dosing regimen and administration context. The medicine is intended for intermittent use and is not prescribed as a long-term therapy.

Standard Dosage and Frequency

The standard single dose for adults and adolescents 12 years of age and older is 2 caplets (or tablets). This dose delivers 1,000 mg of acetaminophen, 120 mg of caffeine, and 30 mg of pyrilamine maleate per administration. Dosing follows an as-needed schedule with the dose being taken every 6 hours, defining the mandatory minimum interval between doses.

Administration Protocol and Limits

Administration requires the caplets to be swallowed whole with water. The primary constraint on usage is the maximum daily intake. The maximum intake is a total of 6 caplets in any 24-hour period. This limit manages the total daily dose of all active components, particularly ensuring that the 3,000 mg acetaminophen daily total is not surpassed when using this specific product. Furthermore, because of the caffeine component, a special procedural condition is that the use of other caffeine-containing foods, beverages, or medications must be limited during the treatment period. For children under 12 years of age, instructions specify that a healthcare professional must be consulted before use.

Research Evidence / Overview of Studies for Syncol Max

The research base for Syncol Max focuses on studies that examined the specific combination of its three active components—Acetaminophen, Caffeine, and Mepyramine maleate—in the context of conditions characterized by fluctuating or episodic manifestations, studying outcomes related to physical discomfort.

Evidence from Studies for Menstrual Symptoms (Dysmenorrhea)

Research exploring this fixed-dose combination was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews focused on symptoms related to the menstrual cycle. These studies monitored outcomes related to physical discomfort, such as pain scores, and evaluated functional status during symptomatic periods. Regulatory summaries have contributed to the evidence landscape by noting that combining the components was associated with different outcome patterns compared to single-ingredient components. Long-term patterns are not fully established regarding the management of monthly symptoms.

Evidence from Studies for General Acute Pain

The core combination was evaluated in a large body of research, including high-quality Meta-analyses of RCTs. These studies explored outcomes related to physical discomfort in populations experiencing various pain models. Research highlights changes measured during the study period, indicating that the inclusion of the caffeine component with Acetaminophen was associated with different patterns in the measured outcomes compared to Acetaminophen alone. Follow-up durations were limited in most acute pain studies, and comparative evidence is lacking for how this specific three-component formulation performs against other single-ingredient or two-component products was observed in trials.

Evidence for Associated Symptom Modulation (Bloating/Water Retention)

The third component, Mepyramine maleate, was evaluated in the context of the associated symptom of bloating and water-weight gain. The evidence for this specific application is largely derived from Regulatory Monograph history and evidence describing how symptoms are measured as outcomes related to systemic or functional imbalance. Evidence quality varies across studies, and the existing studies provide limited insight into the relative contribution of this component when used simultaneously with the other two ingredients.

Long-Term Studies and Follow-up

Research primarily examined the combination in studies conducted during periods of increased symptom activity where the research focus was on temporary symptom management. The available evidence is largely concentrated in short-term trials with limited follow-up durations. Data related to the durability of response or any potential changes with frequent, prolonged use are not fully established.

Evidence in Special Populations

The main research was conducted in adult female cohorts experiencing conditions involving periods of heightened symptoms. Data for certain groups remain insufficient. For instance, while some studies included adolescents, evidence for older adults or individuals with significant underlying health conditions remains limited. Results apply only to the populations studied, and subgroup findings are uncertain when moving outside the primary populations.

What Remains Uncertain About Syncol Max Evidence

The existing research highlights several limitations. Sample sizes were modest in some key studies, and evidence quality varies across studies when comparing the two-component evidence base to the three-component evidence base. Key areas where data are still emerging include understanding the specific, independent action of the third component within the combination and establishing comprehensive data on long-term effects related to repeated use.

Key Studies & References

1. DailyMed Label for Midol Complete (Acetaminophen, Caffeine, and Pyrilamine Maleate Tablets)
2. Systematic Review of Acetaminophen and Nonsteroidal Anti-inflammatory Drugs for Menstrual Pain

Common questions about Syncol Max (FAQ)

Q: Why is Syncol Max sometimes positioned differently than other pain relievers?

Studies have examined this fixed-dose combination, and the research indicates that combining acetaminophen with an adjuvant, like caffeine, was associated with different outcomes compared to using acetaminophen alone. Official product documents describe the combination as intended for broader symptomatic relief by combining multiple active ingredients.

Q: Are there any common over-the-counter supplements that interact with Syncol Max?

Official regulatory guidance requires limiting the intake of other products containing caffeine, which includes many over-the-counter supplements and beverages. While the label specifies warnings for certain medications, official information advises consulting a healthcare professional regarding the use of any other supplements or medicines taken concurrently.

Q: Can Syncol Max cause long-term problems with the liver or kidneys?

Official product information notes the risk of severe liver damage, which is substantially increased by exceeding the maximum daily dose. The regulatory research summaries state that the long-term safety patterns related to frequent, prolonged use are not fully established, and kidney effects are not specifically listed as a common risk.

Q: Is Syncol Max a non-steroidal anti-inflammatory drug (NSAID)?

Official documents classify Syncol Max as an Analgesic Combination due to its composition. This means it contains the non-opioid analgesic acetaminophen, and the combination is not classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: Is Syncol Max appropriate for older adults (seniors) to take?

Official product information advises professional consultation before use for specific conditions, such as glaucoma or an enlarged prostate gland, which are more common in older adults. Furthermore, research evidence for this combination in older adult populations is documented as being limited, according to official summaries.

Q: Why is Syncol Max not generally recommended for people with a history of heart problems?

The product contains caffeine, which functions as a Central Nervous System (CNS) stimulant. Official safety information links the caffeine component to dose-related effects such as nervousness, sleeplessness, and occasionally, a rapid heartbeat.

Q: Is 'Syncol Max' the brand name, and what are the generic names of its components?

Syncol Max is the trade name for this product, which is officially defined as a fixed-dose combination. The drug is composed of three distinct active ingredients: Acetaminophen, Caffeine, and Mepyramine maleate. Other products containing the same active components may be available on the market.

Q: Can Syncol Max be taken at the same time as cold and flu remedies?

Regulatory documents formally prohibit co-administration with any other drug containing acetaminophen to prevent the risk of severe liver damage. Due to the formal prohibition on co-administration with any other acetaminophen-containing drug, official warnings state that using these products concurrently is not allowed.

Q: How long after taking Syncol Max can I take another type of pain reliever?

The minimum interval between doses of Syncol Max is six hours, and the regulatory label prohibits use with other acetaminophen-containing medicines at any time. For using a different class of pain-relieving medicine, official guidance advises consulting a healthcare professional.

Q: Does Syncol Max come in different strengths or forms (tablet, liquid)?

The product is officially described and formulated as an oral preparation in a tablet or caplet form. The regulatory documents define the standard dose and ingredient composition based on this specific oral form only.

Q: Does Syncol Max have any effect on mental clarity or focus?

The drug contains components that affect the Central Nervous System (CNS). The caffeine component, a CNS stimulant, is associated with nervousness and sleeplessness, while the antihistamine component is associated with drowsiness.

Q: What is the best way to store Syncol Max, and what is its shelf life?

Official guidance indicates that the product should be stored at controlled room temperature, which is approximately 25^circC (77^circF). The shelf life or expiration period for the medication is based on the date printed on the original product packaging.

Q: Are there specific populations or ethnicities where Syncol Max works differently?

Official research summaries state that the results from clinical studies apply only to the specific populations that were studied. Subgroup findings are noted as being uncertain when moving outside of the primary study populations.

Q: Does Syncol Max have a 'Black Box Warning' in the US?

The regulatory information for the active ingredient, acetaminophen, carries the agency's most serious warning concerning the potential for severe liver injury (hepatotoxicity) and serious skin reactions. This warning is intended to highlight the critical risks associated with the ingredient.

Q: What should be done if a dose of Syncol Max is forgotten?

Official regulatory documents define the minimum interval between doses as six hours, and state that the maximum daily limit should not be exceeded. Specific instructions for managing a forgotten dose are not typically provided in the non-prescription product labels.

Q: Is there a recommended time of day to take Syncol Max for the best effect?

Official regulatory documents define the schedule for use as as-needed with a minimum interval between doses. They do not specify or recommend a preferred time of day for administration to achieve the best effect.

Q: Why do official documents mention the eye condition glaucoma with Syncol Max?

The regulatory label advises consultation with a healthcare professional before use if an individual has glaucoma, which is a condition affecting the eyes. This is listed under conditional uses, while vision changes are not listed as a common side effect in the official safety information.

Q: Is Syncol Max classified as a controlled substance?

Official drug classifications define the product as an Analgesic Combination. None of the drug's three active ingredients are currently classified as controlled substances.

Q: What are the reasons that necessitate stopping Syncol Max treatment?

Regulatory documents specify serious conditions that contraindicate use, such as the development of an allergic reaction or signs of liver damage. The appearance of these conditions is noted as a reason for prompt cessation of the product’s use, as per official warnings.

How to Store and Dispose of Syncol Max

Storage Requirements

Syncol Max tablets must be stored at controlled room temperature, specifically 25 C (77 F). Brief temperature excursions are permitted between 15 C and 30 C (59 F and 86 F). The product packaging is tamper-evident, and the medication must not be used if the outer package is open or the blister pack is torn or broken.

Safety and Disposal

Due to the active ingredients, it is a mandatory requirement to keep Syncol Max out of the reach of children at all times. For disposal of unused or expired tablets, official guidance recommends utilizing a community drug take-back program. If a take-back program is unavailable, medicines should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. This product is not on the list of medicines recommended for flushing.